Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 rilzabrutinib dose-ranging study in chronic spontaneous urticaria
NL-OMON51643Phase 2Recruiting
- Sponsor
- Sanofi
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rilzabrutinib in chronic idiopathic urticaria (CIU) (3 arms), sponsored by Sanofi. Started Nov 2022; status: recruiting.
02
Drugs
rilzabrutinib
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on NL-OMON51643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51643.